Tyra Biosciences (NASDAQ:TYRA - Get Free Report) issued its earnings results on Thursday. The company reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.05, Zacks reports.
Tyra Biosciences Trading Down 0.2 %
TYRA stock traded down $0.02 during midday trading on Tuesday, reaching $9.29. The stock had a trading volume of 304,390 shares, compared to its average volume of 233,215. Tyra Biosciences has a 52-week low of $8.84 and a 52-week high of $29.60. The company has a market cap of $469.85 million, a price-to-earnings ratio of -5.76 and a beta of 1.09. The company's fifty day simple moving average is $12.32 and its 200 day simple moving average is $16.22.
Analyst Ratings Changes
Several equities analysts recently weighed in on the company. Wedbush restated an "outperform" rating and issued a $30.00 price target on shares of Tyra Biosciences in a research note on Friday. UBS Group began coverage on shares of Tyra Biosciences in a report on Tuesday, January 7th. They issued a "buy" rating and a $28.00 price target for the company. Finally, HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of Tyra Biosciences in a research note on Monday. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Tyra Biosciences currently has a consensus rating of "Buy" and a consensus price target of $30.83.
Get Our Latest Stock Analysis on Tyra Biosciences
Insider Transactions at Tyra Biosciences
In related news, Director Nina S. Kjellson sold 5,401 shares of the business's stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total transaction of $74,317.76. Following the transaction, the director now directly owns 443,885 shares in the company, valued at approximately $6,107,857.60. The trade was a 1.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders sold 21,998 shares of company stock valued at $344,818 over the last 90 days. 15.40% of the stock is currently owned by corporate insiders.
About Tyra Biosciences
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
See Also
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
